Oritavancin (formerly known as LY333328; LY-333328; Orbactiv) is a novel semisynthetic glycopeptide antibiotic medication approved for the treatment of serious Gram-positive bacterial infections. It is a lipoglycopeptide analog of vancomycin containing the heptapeptide core common to all glycopeptides. On August 6, 2014, the FDA approved oritavancin for treatment of skin infections. Oritavancin possesses potent and rapid bactericidal activity in vitro against a broad spectrum of both resistant and susceptible Gram-positive bacteria, including Staphylococcus aureus, MRSA, enterococci, and streptococci. Oritavancin was more active than either metronidazole or vancomycin against strains of Clostridium difficile tested. Oritavancin has potential use as a therapy for exposure to Bacillus anthracis, the Gram-positive bacterium that causes anthrax, having demonstrated efficacy in a mouse model both before and after exposure to the bacterium.

纯度：≥98%

CAS：171099-57-3